1380424-42-9 Usage
Description
Endocannabinoids such as 2-arachidonoyl glycerol (2-AG) and arachidonoyl ethanolamide are biologically active lipids that are involved in a number of synaptic processes including activation of cannabinoid receptors. Monoacylglycerol lipase (MAGL) is a serine hydrolase responsible for the hydrolysis of 2-AG to arachidonic acid and glycerol, thus terminating its biological function. KML29 is an O-hexafluoroisopropyl carbamate analog of JZL 184 that potently and selectively inhibits MAGL (IC50s = 15, 43, and 5.9 nM in mouse, rat, and human brain proteomes, respectively) over FAAH (IC50s >50 μM). At 5-20 mg/kg, KML29 dose-dependently blocks mouse brain MAGL activity in vivo, without any measurable effect on FAAH activity. As a second generation MAGL inhibitor, KML29 supersedes the low-level cross reactivity that JZL 184 displays for FAAH yet still maintains comparable potency to its parent compound.
Uses
KML-29 is an extremely specific monoacylglycerol lipase (MAGL) inhibitor. KML-2 should be useful to distinguish between actions of 2-arachidonoyl glycerol (an endogenous ligand of cannabinoid receptors that is deactivated by MAGL) and anandamide, another endocannabinoid.
Check Digit Verification of cas no
The CAS Registry Mumber 1380424-42-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,8,0,4,2 and 4 respectively; the second part has 2 digits, 4 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1380424-42:
(9*1)+(8*3)+(7*8)+(6*0)+(5*4)+(4*2)+(3*4)+(2*4)+(1*2)=139
139 % 10 = 9
So 1380424-42-9 is a valid CAS Registry Number.
1380424-42-9Relevant articles and documents
CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME
-
, (2013/07/19)
This disclosure provides compounds and compositions which may be modulators of MAGL and/or ABHD6 and their use as medicinal agents, processes for their preparation, and pharmaceutical compositions that include disclosed compunds as at least one active agent. The disclosure also provides for method of treating a patient in need thereof, where the patient is suffering from indications such as pain, solid tumor cancer and/or obesity comprising administering a disclosed compound or composition.
